BR0311254A - Composto, kit contraceptivo e/ou de hrt, uso de uma quantidade contraceptiva e/ou terapeuticamente eficaz de um composto, e, métodos de contracepção e/ou hrt, e de tratamento e/ou de prevenção de um distúrbio ginecológico feminino - Google Patents

Composto, kit contraceptivo e/ou de hrt, uso de uma quantidade contraceptiva e/ou terapeuticamente eficaz de um composto, e, métodos de contracepção e/ou hrt, e de tratamento e/ou de prevenção de um distúrbio ginecológico feminino

Info

Publication number
BR0311254A
BR0311254A BR0311254-3A BR0311254A BR0311254A BR 0311254 A BR0311254 A BR 0311254A BR 0311254 A BR0311254 A BR 0311254A BR 0311254 A BR0311254 A BR 0311254A
Authority
BR
Brazil
Prior art keywords
contraceptive
compound
hrt
contraception
prevention
Prior art date
Application number
BR0311254-3A
Other languages
English (en)
Inventor
Henrik De Nijs
Hendrikus Adrianus Anton Voort
Dirk Leysen
Arij Jan Grootenhuis
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of BR0311254A publication Critical patent/BR0311254A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0096—Alkynyl derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMPOSTO, KIT CONTRACEPTIVO E/OU DE HRT, USO DE UMA QUANTIDADE CONTRACEPTIVA E/OU TERAPEUTICAMENTE EFICAZ DE UM COMPOSTO, E, MéTODOS DE CONTRACEPçãO E/OU HRT, E DE TRATAMENTO E/OU DE PREVENçãO DE UM DISTúRBIO GINECOLóGICO FEMININO". A presente invenção proporciona novos ésteres de progestógenos e seus usos
BR0311254-3A 2002-05-30 2003-05-22 Composto, kit contraceptivo e/ou de hrt, uso de uma quantidade contraceptiva e/ou terapeuticamente eficaz de um composto, e, métodos de contracepção e/ou hrt, e de tratamento e/ou de prevenção de um distúrbio ginecológico feminino BR0311254A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02077119 2002-05-30
PCT/EP2003/050187 WO2003102012A2 (en) 2002-05-30 2003-05-22 New etonogestrel esters

Publications (1)

Publication Number Publication Date
BR0311254A true BR0311254A (pt) 2005-03-15

Family

ID=29595014

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0311254-3A BR0311254A (pt) 2002-05-30 2003-05-22 Composto, kit contraceptivo e/ou de hrt, uso de uma quantidade contraceptiva e/ou terapeuticamente eficaz de um composto, e, métodos de contracepção e/ou hrt, e de tratamento e/ou de prevenção de um distúrbio ginecológico feminino

Country Status (31)

Country Link
US (1) US7323454B2 (pt)
EP (1) EP1513861B1 (pt)
JP (1) JP4716726B2 (pt)
KR (1) KR20050009723A (pt)
CN (2) CN1314701C (pt)
AR (1) AR040130A1 (pt)
AT (1) ATE349458T1 (pt)
AU (1) AU2003238081B2 (pt)
BR (1) BR0311254A (pt)
CA (1) CA2487722C (pt)
CO (1) CO5631449A2 (pt)
DE (1) DE60310714T2 (pt)
DK (1) DK1513861T3 (pt)
ES (1) ES2277085T3 (pt)
HK (1) HK1072609A1 (pt)
HR (1) HRP20041101A2 (pt)
IL (1) IL165087A0 (pt)
IS (1) IS2421B (pt)
MX (1) MXPA04011797A (pt)
NO (1) NO20044898L (pt)
NZ (1) NZ536619A (pt)
PE (1) PE20040068A1 (pt)
PL (1) PL373855A1 (pt)
PT (1) PT1513861E (pt)
RS (1) RS97604A (pt)
RU (1) RU2325910C2 (pt)
SI (1) SI1513861T1 (pt)
TW (1) TW200403065A (pt)
UA (1) UA80126C2 (pt)
WO (1) WO2003102012A2 (pt)
ZA (1) ZA200410410B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200400041A (en) * 2002-05-30 2004-01-01 Akzo Nobel Nv Use of new etonogestrel esters
US20090062909A1 (en) 2005-07-15 2009-03-05 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
ES2691646T3 (es) 2005-07-15 2018-11-28 Micell Technologies, Inc. Revestimientos poliméricos que contienen polvo de fármaco de morfología controlada
EP2944382A1 (en) 2006-04-26 2015-11-18 Micell Technologies, Inc. Coatings containing multiple drugs
CN101711137B (zh) 2007-01-08 2014-10-22 米歇尔技术公司 具有可生物降解层的支架
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
EP2271294B1 (en) 2008-04-17 2018-03-28 Micell Technologies, Inc. Stents having bioabsorbable layers
US9510856B2 (en) 2008-07-17 2016-12-06 Micell Technologies, Inc. Drug delivery medical device
AU2009270849B2 (en) 2008-07-17 2013-11-21 Micell Technologies, Inc. Drug delivery medical device
WO2010111232A2 (en) 2009-03-23 2010-09-30 Micell Technologies, Inc. Drug delivery medical device
WO2010120552A2 (en) 2009-04-01 2010-10-21 Micell Technologies, Inc. Coated stents
WO2010121187A2 (en) 2009-04-17 2010-10-21 Micell Techologies, Inc. Stents having controlled elution
US11369498B2 (en) 2010-02-02 2022-06-28 MT Acquisition Holdings LLC Stent and stent delivery system with improved deliverability
US10232092B2 (en) 2010-04-22 2019-03-19 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
CA2805631C (en) 2010-07-16 2018-07-31 Micell Technologies, Inc. Drug delivery medical device
CA2841360A1 (en) 2011-07-15 2013-01-24 Micell Technologies, Inc. Drug delivery medical device
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
US11039943B2 (en) 2013-03-12 2021-06-22 Micell Technologies, Inc. Bioabsorbable biomedical implants
JP2016519965A (ja) 2013-05-15 2016-07-11 マイセル・テクノロジーズ，インコーポレイテッド 生体吸収性バイオメディカルインプラント
RU2595818C1 (ru) * 2015-05-25 2016-08-27 Федеральное государственное бюджетное научное учреждение "Научный центр проблем здоровья семьи и репродукции человека" Способ комплексного лечения дисфункции яичников при применении гормонального контрацептива имплантата "импланона"
CN111057120B (zh) * 2019-12-27 2021-04-27 苏州翔实医药发展有限公司 一种依托孕烯衍生物a及其制备方法和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB845442A (en) 1956-03-22 1960-08-24 Schering Ag Manufacture of steroid compounds
DE1013284B (de) 1956-03-22 1957-08-08 Schering Ag Verfahren zur Einfuehrung der Reste wenig reaktionsfaehiger Carbonsaeuren, insbesondere des ª‰-Cyclopentyl-propionylrestes, in die 17ª‡-staendige Oxygruppe solcher Steroide, die am Kohlenstoffatom 17 neben der Oxygruppe eine Acetylgruppe tragen
GB8313921D0 (en) * 1983-05-19 1983-06-22 World Health Org Contraceptive compositions
DE4227989A1 (de) 1992-08-21 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel
DE4240806A1 (de) 1992-12-01 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 14alpha,17alpha-Ethanoestra-1,3,5(10)-trien-3,17beta-diol
JPH07101884A (ja) 1993-10-01 1995-04-18 Sanei Gen F F I Inc 水溶性ヘミセルロースを含有する製剤
WO1995017896A1 (fr) * 1993-12-27 1995-07-06 Akzo Nobel N.V. Preparation pour absorption par voie percutanee
DE19613698A1 (de) * 1995-07-17 1997-01-23 Schering Ag Mittel zur transdermalen Applikation enthaltend Ester des 13-Ethyl-17ß-hydroxy-11-methylen-18,19-dinor-17alpha-pregn-4-en-20-yn-3-ons
AU6614096A (en) * 1995-07-17 1997-02-18 Schering Aktiengesellschaft Agent, for transdermal application, containing esters of 3-ketodesogestrel
AU4513099A (en) 1998-06-19 2000-01-10 Akzo Nobel N.V. Cycloalkyl-carboxylic acid esters of 7.alpha.methyl-estr-4-en-3-one 17.beta.-ol (19-nor 7.alpha.-methyltestosterone)
TR200003743T2 (tr) 1998-06-19 2001-07-23 Akzo Nobel N.V. Testosteron türevi.
US6180682B1 (en) 1999-01-26 2001-01-30 Virgil A. Place Buccal drug delivery system for use in male contraception
TW200400041A (en) * 2002-05-30 2004-01-01 Akzo Nobel Nv Use of new etonogestrel esters

Also Published As

Publication number Publication date
SI1513861T1 (sl) 2007-06-30
PL373855A1 (en) 2005-09-19
UA80126C2 (en) 2007-08-27
WO2003102012A9 (en) 2005-01-13
EP1513861A2 (en) 2005-03-16
KR20050009723A (ko) 2005-01-25
RS97604A (en) 2006-10-27
CA2487722C (en) 2011-07-19
DE60310714T2 (de) 2007-10-11
IL165087A0 (en) 2005-12-18
HRP20041101A2 (en) 2004-12-31
HK1072609A1 (en) 2005-09-02
ZA200410410B (en) 2006-02-22
DK1513861T3 (da) 2007-04-10
US20050222113A1 (en) 2005-10-06
AU2003238081B2 (en) 2008-09-18
CA2487722A1 (en) 2003-12-11
PE20040068A1 (es) 2004-02-18
US7323454B2 (en) 2008-01-29
EP1513861B1 (en) 2006-12-27
IS7528A (is) 2004-11-15
IS2421B (is) 2008-10-15
RU2325910C2 (ru) 2008-06-10
MXPA04011797A (es) 2005-03-31
AR040130A1 (es) 2005-03-16
JP4716726B2 (ja) 2011-07-06
TW200403065A (en) 2004-03-01
CO5631449A2 (es) 2006-04-28
CN1692122A (zh) 2005-11-02
DE60310714D1 (de) 2007-02-08
PT1513861E (pt) 2007-03-30
CN1314701C (zh) 2007-05-09
NZ536619A (en) 2007-09-28
ES2277085T3 (es) 2007-07-01
ATE349458T1 (de) 2007-01-15
NO20044898L (no) 2005-02-25
RU2004138807A (ru) 2005-05-27
WO2003102012A3 (en) 2004-04-22
WO2003102012A2 (en) 2003-12-11
AU2003238081A1 (en) 2003-12-19
JP2005532350A (ja) 2005-10-27
CN101100480A (zh) 2008-01-09

Similar Documents

Publication Publication Date Title
BR0311254A (pt) Composto, kit contraceptivo e/ou de hrt, uso de uma quantidade contraceptiva e/ou terapeuticamente eficaz de um composto, e, métodos de contracepção e/ou hrt, e de tratamento e/ou de prevenção de um distúrbio ginecológico feminino
TR200200706T2 (tr) Nöropatik ağrı tedavisi için retigabin kullanımı.
BR0214705A (pt) Composição, seu uso, método para prevenção ou tratamento de doença neurodegenerativa, e kit
NO20034056D0 (no) Proliferative sykdommer
IL142768A0 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
DE69925133D1 (de) Pyrrolobenzodiazepine
BR0211769A (pt) Combinações antineoplásicas
GEP20094780B (en) Prostaglandin nitrooxyderivatives
CA2260145A1 (en) Use of l-acetylcarnitine, l-isovalerylcarnitine, l-propionylcarnitine for increasing the levels of igf-1
EP1186293A3 (en) Intermittent administration of a growth hormone secretagogue
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
WO1999064059A3 (en) Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
AU3126600A (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU2160492A (en) Treatment of human diseases involving dysregulation or dysfunction of the nervous system
BR0309095A (pt) Uso de osteoprotegerina para o tratamento e/ou prevenção de doença fibrótica
IT1285770B1 (it) Composti corticoidei
BR0111892A (pt) Bis-arilsulfonas
TR200301330T2 (tr) Miyelin kaybettiren hastalıkların veya durumların tedavi yöntemi.
DE60325377D1 (de) Motilidverbindungen
MXPA03003741A (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
SE9201930D0 (sv) Gastric antibacterial treatment
AU4179399A (en) Use of nmda antagonists and/or sodium channel antagonists for the treatment of inflammatory disorders
BR9713176A (pt) Benzotiofenos amorfos,métodos de preparação e métodos de uso
BR0210632A (pt) Tratamento de doença parasìtica

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: N.V. ORGANON (NL)

Free format text: TRANSFERIDO DE: AKZO NOBEL N.V.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2116 DE 26/07/2011.